Board-certified rheumatologist/immunologist. Venture Partner of Bay City Capital from 2007-2014. Previously: President and CEO of Berlex Biosciences (US arm of Schering AG) acquired by Bayer. Dr. Perez is on the Board of Directors of Presidio Pharmaceuticals, Celtaxsys (private companies), the Scientific Advisory Board of Cardium , the Investment Board of Glaxo GSK, China and the President’s Council for the Gladstone Institutes at the University of California, San Francisco (UCSF). He was a member of the Board of Directors of BayBio, Cleveland Biolabs and Hyperion Therapeutics.